KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

doi:10.3389/fonc.2021.672612

	KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
	Xie, Mingying 2; Xu, Xiaoling 1,3,4; Fan, Yun 1,3,4
刊名	FRONTIERS IN ONCOLOGY
	2021-05-03
卷号	11
关键词	KRAS-mutant NSCLC targeted therapy immunotherapy AMG510 MRTX849
ISSN号	2234-943X
DOI	10.3389/fonc.2021.672612
通讯作者	Fan, Yun(fanyun@zjcc.org.cn)
英文摘要	Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in NSCLC, are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted drugs. The latest published clinical trial data on new small-molecule KRAS G12C inhibitors, AMG510 and MRTX849, indicate that these molecules may potentially help treat KRAS-mutant NSCLC. Simultaneously, within the immuno-therapeutic process, immune efficacy has been observed in those patients who have KRAS mutations. In this article, the pathogenesis, treatment status, progress of immunotherapy, and targeted therapy of KRAS-mutant NSCLC are reviewed.
资助项目	Natural Scientific Foundation of China[81972718] ; Natural Scientific Foundation of Zhejiang Province, China[LY19H160007]
WOS关键词	INHIBITOR ; CONFERS
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000651054400001
资助机构	Natural Scientific Foundation of China ; Natural Scientific Foundation of Zhejiang Province, China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/122092]
专题	中国科学院合肥物质科学研究院
通讯作者	Fan, Yun
作者单位	1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Zhejiang Chinese Med Univ, Dept Med Oncol, Clin Med Coll 2, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xie, Mingying,Xu, Xiaoling,Fan, Yun. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup[J]. FRONTIERS IN ONCOLOGY,2021,11.
APA	Xie, Mingying,Xu, Xiaoling,&Fan, Yun.(2021).KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.FRONTIERS IN ONCOLOGY,11.
MLA	Xie, Mingying,et al."KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup".FRONTIERS IN ONCOLOGY 11(2021).